{"id":"flutazolam","rwe":[{"pmid":"27366870","year":"2017","title":"Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.","finding":"","journal":"Drug testing and analysis","studyType":"Clinical Study"},{"pmid":"2898425","year":"1988","title":"[Studies on the clinical significance concerning the changes in serum pepsinogen-I and gastrin levels in aged patients with chronic gastritis].","finding":"","journal":"[Hokkaido igaku zasshi] The Hokkaido journal of medical science","studyType":"Clinical Study"},{"pmid":"2894449","year":"1987","title":"[The behavior of 1,4-benzodiazepine drugs in acidic media. IX. Effect of hydrolyzate of flutazolam on the central nervous system].","finding":"","journal":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","studyType":"Clinical Study"},{"pmid":"2870816","year":"1986","title":"The behavior of 1,4-benzodiazepine drugs in acidic media. V. Kinetics of hydrolysis of flutazolam and haloxazolam in aqueous solution.","finding":"","journal":"Chemical & pharmaceutical bulletin","studyType":"Clinical Study"},{"pmid":"750333","year":"1978","title":"[Psychopharmacological effects of flutazolam (MS-4101) (author's transl)].","finding":"","journal":"Nihon yakurigaku zasshi. Folia pharmacologica Japonica","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"coreminal","offLabel":[],"synonyms":["flutazolam","coreminal"],"timeline":[],"approvals":[],"brandName":"Coreminal","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your brain is a city with many different neighborhoods, each with its own unique culture and way of communicating. Flutazolam is like a special key that unlocks certain neighborhoods, allowing them to talk to each other in new and different ways. This can help to regulate mood and other brain functions.","oneSentence":"Flutazolam is a small molecule that modulates neurotransmitter activity in the brain.","technicalDetail":"Flutazolam is a small molecule that acts as a GABA_A receptor modulator, potentially influencing the activity of GABA, a major inhibitory neurotransmitter in the brain."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1224","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUTAZOLAM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:36:44.065237","biosimilars":[],"competitors":[],"genericName":"flutazolam","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"5G2K7O5D8S","CHEBI":"CHEBI:31628","INN_ID":"3682","UMLSCUI":"C0060593","ChEMBL_ID":"CHEMBL1697836","KEGG_DRUG":"D01286","PUBCHEM_CID":"3398","MESH_SUPPLEMENTAL_RECORD_UI":"C013367"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2017 Apr","pmid":"27366870","title":"Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.","journal":"Drug testing and analysis"},{"date":"1988 Mar","pmid":"2898425","title":"[Studies on the clinical significance concerning the changes in serum pepsinogen-I and gastrin levels in aged patients with chronic gastritis].","journal":"[Hokkaido igaku zasshi] The Hokkaido journal of medical science"},{"date":"1987 Oct","pmid":"2894449","title":"[The behavior of 1,4-benzodiazepine drugs in acidic media. IX. Effect of hydrolyzate of flutazolam on the central nervous system].","journal":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan"},{"date":"1986 Jan","pmid":"2870816","title":"The behavior of 1,4-benzodiazepine drugs in acidic media. V. Kinetics of hydrolysis of flutazolam and haloxazolam in aqueous solution.","journal":"Chemical & pharmaceutical bulletin"},{"date":"1978 Nov","pmid":"750333","title":"[Psychopharmacological effects of flutazolam (MS-4101) (author's transl)].","journal":"Nihon yakurigaku zasshi. Folia pharmacologica Japonica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Flutazolam, also known as Coreminal, is a small molecule compound with unknown target and drug class. Its development and current ownership are not publicly disclosed. The compound is not FDA-approved for any indications. The commercial status of flutazolam is unclear, and it is not known whether it is patented or available as a generic. Key safety considerations are unknown due to the lack of available information.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}